In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting ...

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...

RiDYMO® has been successfully employed in various drug discovery programs, including the development of small molecule ...

New research shows how regular aspirin use can lower cancer risk, especially for those with unhealthy lifestyles. Discover ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Colorectal Cancer.

Despite advancements in cancer treatment technologies, most therapies share a common goal: eliminating cancer cells. However, ...

INR:9989. poker blinds Vicinium for the treatment of bladder cancer has clear EU regulatory pathway and is entering rolling review in the US! CPP-1X/sul for the trea ...

Scientists at KAIST have developed a groundbreaking method to convert colon cancer cells into healthy ones using a ...

KAIST researchers have developed new technology that can transform colon cancer cells into normal-like cells. Led by ...

A groundbreaking FDA approval has introduced a new treatment option specifically designed for colorectal cancer patients with ...

The following is a summary of “Current status of serum metabolites biomarkers for polyps and colorectal cancer: a systematic ...